News

CNM-Au8, an experimental oral treatment by Clene Nanomedicine, was safe and led to improvements in the brain’s energetic profile — thought to protect against cell death — in adults with Parkinson’s disease, according to data from the Phase 2 clinical trial REPAIR-PD. “In addition to achieving its primary…

The response of the eyes’ pupils — the black circle in the center of the eye  that allows light to enter — seems to change according to the progression of Parkinson’s disease, a recent study has found. The results suggest that measuring the pupils’ response to stimuli could become a noninvasive…

Taking inspiration from carnivorous plants, researchers in Korea have developed new technology that may increase the longevity of surgical devices implanted into the brain. The research may lead to improvements in deep brain stimulation (DBS) — a surgical treatment for Parkinson’s disease that involves inserting a device that…

Researcher Amir Hirsa has found a way 240 miles above the Earth’s surface to study the aggregation of proteins that are the hallmarks of Alzheimer’s and Parkinson’s diseases, and type 2 diabetes. Hirsa, PhD, is a professor of mechanical and aerospace engineering with a joint appointment in chemical and biological engineering…

Early Parkinson’s patients with rapid eye movement sleep behavior disorder (RBD) have more severe symptoms and show a faster disease progression in terms of motor, mood, and cognitive symptoms, according to a U.K. study. Moreover, these patients had a higher risk of frequent falls, freezing of gait — when…

Top-line results are expected to be released by the end of this year for Pharma Two B’s multinational trial investigating the safety and efficacy of P2B001 for treating early stage Parkinson’s disease. Pharma Two B announced that its researchers have finished treating patients in the Phase 3 trial, which…

Several new clinical trial data analyses support the benefits and superiority of Gocovri (amantadine) over other therapies in lessening off episodes — periods when levodopa treatments stop working and motor symptoms return — and involuntary movements called dyskinesia in people with Parkinson’s disease. These analyses compared Gocovri, marketed by…

Using a novel approach, called Placebell, could help researchers in clinical trials to understand the placebo effect in people with Parkinson’s disease, and boost the strength of their findings. Researchers at Tools4Patient, which is developing Placebell, and other institutions presented data on the approach at the…

Studies on twins and families have suggested that susceptibility to Parkinson’s disease has a substantial genetic component. Now, an analysis of gene activity in different brain tissues has identified gene candidates that may be directly involved in causing the neurodegenerative disorder. The study, “A transcriptome-wide association study…

The Parkinson’s Foundation is launching a four-year, $30-million fundraising campaign to help advance Parkinson’s research and fund community services. The Reach Further campaign seeks to help accelerate research, increase patient access to healthcare, and enrich community services for those affected by Parkinson’s disease. “With the rate of…